The primary catalyst is the CHAPTER-3 topline data expected in 3Q2026, which will determine the viability of deucrictibant XR for HAE prophylaxis. The FDA PDUFA date for deucrictibant IR is April 23, 2027. Monitor for CHAPTER-3 data release and any regulatory updates.
Drug in focus
PHVS drug pipeline →deucrictibant
◆ Mixed Named in this press release- Impact
- Phase
- Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
- Time to market
- IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
- Next catalyst
- None dated
What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $36.46entry
- T+1 · 3mo ago −6.64%α −7.34% · $34.04
- T+5 · 3mo ago −0.52%α −0.08% · $36.27
- T+20 · 2mo ago +2.88%α +4.78% · $37.51
- T+60 · 12d ago −5.84%α −0.97% · $34.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris reported Q2 2026 results with a loss per share of €0.70, slightly above the consensus EPS estimate of -$0.65 (per ADS) but the comparison is not directly comparable due to currency and share basis differences. The key event is the expected topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, which is the primary stock-moving catalyst.
Key Financial Metrics
Key Facts
- Cash and cash equivalents of €318 million as of June 30, 2026, extending cash runway into 2028
- Loss for Q2 2026 was €47.8 million, or €0.70 per share, vs €45.5 million (€0.83 per share) in Q2 2025
- Topline data from CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis expected in 3Q2026
- FDA accepted NDA for deucrictibant IR with PDUFA date of April 23, 2027; EMA validated MAA in July 2026
- Closed $132.3 million underwritten offering in May 2026
- R&D expenses increased to €35.0 million from €29.6 million YoY; G&A expenses rose to €15.8 million from €10.8 million
Financial Impact
No revenue; net loss of €47.8 million in Q2 2026; cash burn rate approximately €26 million per quarter (based on cash decrease from €292M to €318M, net of $132M offering proceeds)
Risk Factors
- CHAPTER-3 Phase 3 data may fail to meet primary endpoints, jeopardizing the prophylactic indication
- FDA review of deucrictibant IR NDA could result in a Complete Response Letter or extended review
- Pre-revenue biotech with no approved products; depends on successful clinical and regulatory outcomes
- Currency mismatch: financials reported in EUR, consensus estimates in USD per ADS
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343484 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers